Franklin Genomic Advancements ETF HELX

Medalist Rating as of | See Franklin Templeton Investment Hub

Morningstar’s Analysis HELX

Will HELX outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

null Morningstar Automated Analysis

Morningstar Automated Analysis

Summary

Franklin Genomic Advancements ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings HELX

  • Current Portfolio Date
  • Equity Holdings—
  • Bond Holdings—
  • Other Holdings—
  • % Assets in Top 10 Holdings46.4
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Guardant Health Inc

8.633M
Healthcare

Natera Inc

7.863M
Healthcare

Adaptive Biotechnologies Corp

5.002M
Healthcare

Krystal Biotech Inc

4.782M
Healthcare

Ligand Pharmaceuticals Inc

4.592M
Healthcare

Twist Bioscience Corp

3.671M
Healthcare

BridgeBio Pharma Inc

3.391M
Healthcare

Medpace Holdings Inc

2.881M
Healthcare

Eli Lilly and Co

2.82981,119
Healthcare

Vertex Pharmaceuticals Inc

2.78967,026
Healthcare

Sponsor Center